Comparative Pharmacology
Head-to-head clinical analysis: PLUVICTO versus TECHNETIUM TC99M MERTIATIDE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLUVICTO versus TECHNETIUM TC99M MERTIATIDE KIT.
PLUVICTO vs TECHNETIUM TC99M MERTIATIDE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent that binds to prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells. After binding, the radioactive isotope lutetium-177 emits beta particles, causing DNA damage and cell death.
Technetium Tc99m mertiatide is a radiopharmaceutical that undergoes renal tubular secretion and glomerular filtration, allowing imaging of the kidneys. After intravenous administration, it is primarily taken up by the kidneys and excreted into the urine, providing visualization of renal perfusion and function.
PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) is administered intravenously at a dose of 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses, in combination with a gonadotropin-releasing hormone (GnRH) analog or after prior unilateral orchiectomy.
1 mCi (37 MBq) intravenously as a single dose for renal imaging.
None Documented
None Documented
Effective half-life of lutetium-177 is approximately 160 hours (6.67 days), reflecting both physical decay (T1/2 6.647 days) and biological clearance. Clinical context: Due to physical decay, therapeutic radioactivity decreases to <1% after about 45 days.
Terminal elimination half-life: 1.5–2.1 hours (mean 1.8 h). Effective half-life with Tc-99m decay: physical half-life 6.02 h, biological half-life ~1.8 h, effective half-life ~1.4 h. Clinically, imaging completed within 30–60 min post-injection.
Primarily renal; approximately 60% of administered radioactivity excreted in urine within 24 hours, with gradual elimination thereafter. Biliary/fecal excretion accounts for <15%.
Renal: >90% of injected dose excreted via glomerular filtration and tubular secretion within 24 hours. Biliary/fecal: <1%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical